<DOC>
	<DOCNO>NCT01186328</DOCNO>
	<brief_summary>An experimental drug call EZN-3042 target survivin , protein express leukemia cell relapse promotes leukemia cell grow . The main goal phase I study find dose EZN-3042 safely give without serious side effect alone combination standard chemotherapy drug re-induction .</brief_summary>
	<brief_title>EZN-3042 Administered With Re-induction Chemotherapy Children With Relapsed Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>This phase I multi-site study new investigational agent EZN-3042 , highly effective block survivin inhibit survivin protein expression . Survivin play pivotal role tumor formation inhibit cell death regulate cell cycle progression . The primary objective study EZN-3042 child relapse acute lymphoblastic leukemia ( ALL ) . Patients receive 2 dos EZN-3042 prior initiate systemic therapy vincristine , doxorubicin , prednisone PEG-asparaginase . In addition , blood bone marrow specimens draw measure minimal residual disease ( MRD ) , pharmacokinetic level EZN-3042 survivan expression . The study follow standard 3+3 dose escalation design . We hypothesize EZN-3042 safe , tolerable biologically active , give alone combination standard re-induction chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients must ≥1 ≤ 21 year age originally diagnose acute lymphoblastic leukemia ( ALL ) . Patients must diagnosis second great relapse Bprecursor acute lymphoblastic leukemia ( ALL ) ≥25 % blast bone marrow ( M3 ) , without extramedullary disease . Patients may central nervous system 1 , 2 3 disease . Karnofsky ≥ 50 patient &gt; 10 year age Lansky ≥ 50 patient ≤ 10 year age . Patients relapse receive standard ALL maintenance chemotherapy require waiting period entry onto study . Patients relapse receive standard ALL maintenance therapy must fully recover grade 3 4 toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Cytotoxic Therapy : It must least 14 day since completion cytotoxic therapy ( exclude hydroxyurea ) time study enrollment . Hematopoietic Stem Cell Transplant ( HSCT ) : Patients experience relapse HSCT eligible , provide evidence active GraftversusHost Disease ( GVHD ) least 120 day posttransplant time enrollment . Prior anthracycline exposure : Patients must ≤ 400 mg/m2 lifetime exposure anthracycline chemotherapy . Biologic ( antineoplastic ) therapy : It must least 7 day since completion therapy biologic agent time study enrollment . For agent know adverse event occur 7 day administration , period must extend beyond time adverse event know occur . Patients must calculate creatinine clearance radioisotope GRF ≥ 70mL/min/1.73m2 OR normal serum creatinine base institutional normal value accord age . Patient 's ALT must &lt; 5 x institutional upper limit norm ( ULN ) , unless elevation suspect diseaserelated . Patient 's total bilirubin must ≤ 1.5 x ULN . Patient 's serum albumin must ≥ 2 g/dL . Patient must prothrombin time ( PT ) , partial thromboplastin time ( PTT ) international normalize ratio ( INR ) ≤ 1.5 time ULN . Patient must shorten fraction ≥ 27 % echocardiogram ejection fraction ≥ 45 % gate nucleotide study . Female patient childbearing potential must negative urine serum pregnancy test confirm prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study . Patients Down syndrome exclude . Patients Bcell ALL ( L3 morphology evidence myc translocation molecular cytogenetic technique ) eligible Patients document active uncontrolled infection time study entry eligible . Patient exclude currently receive investigational drug . Patients exclude take strong CYP3A4 inducer inhibitor . Patients exclude plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period . Patients exclude significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Relapse</keyword>
	<keyword>T cell</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>EZN3042</keyword>
	<keyword>Refractory</keyword>
	<keyword>Precursor B</keyword>
	<keyword>Pre B cell</keyword>
	<keyword>Survivan</keyword>
	<keyword>Acute</keyword>
	<keyword>Childhood</keyword>
	<keyword>Pediatric</keyword>
</DOC>